Preferred Drug List (PDL) Changes Effective 5/29/2025

In addition to the May 29, 2025 PDL changes listed below, please be prepared for the following changes coming **July 10, 2025** by transitioning members to the preferred products.

- Generic **albuterol HFA** inhalers will no longer bypass the PDL. Only brand Ventolin HFA will continue to pay without a prior authorization.
- Fluticasone HFA inhalers will move to non-preferred except for children 5 and under. Asmanex HFA (approved down to 5 y.o.) and Alvesco (approved down to 12 y.o.) have been added to the PDL to help mitigate treatment disruptions.

Angiotensin Modulators:

Preferred to Non-Preferred Non-Preferred to Preferred

quinapril

quinapril HCTZ

Beta-Blockers:

Preferred to Non-Preferred Non-Preferred to Preferred

bisoprolol

GI Motility, Chronic:

Preferred to Non-Preferred
Amitiza

Non-Preferred to Preferred
lubiprostone (generic Amitiza)

Corticosteroids Inhaled:

Preferred to Non-Preferred Non-Preferred to Preferred

Alvesco

Asmanex HFA

Insulins:

Preferred to Non-Preferred Non-Preferred to Preferred

Humalog insulin lispro

Novolog insulin aspart cartridge OTC Novolin N and R OTC Humulin N and R

SGLT2s:

Preferred to Non-Preferred Non-Preferred to Preferred

Invokana Invokamet

insulin glargine vial

Phosphate Binders:

Preferred to Non-Preferred Non-Preferred to Preferred

Renvela 800mg tab Sevelamer carbonate 800mg tab

(generic Renvela)

Potassium Binders:

Preferred to Non-Preferred Non-Preferred to Preferred

Lokelma

Proton Pump Inhibitors:

Preferred to Non-Preferred Non-Preferred to Preferred

OTC lansoprazole caps OTC lansoprazole 15mg solutab

Nexium packets Prevacid solutab

Ulcerative Colitis:

Preferred to Non-Preferred Non-Preferred to Preferred meselamine (generic Lialda)

Lialda

Vaginal Estrogens:

Non-Preferred to Preferred Preferred to Non-Preferred

Femring